Exploring CPP Enhanced Hypoxia Targeting: An Approach Using Radiolabeled 2‐nitroimidazole TAT Conjugate
Open Access
- 15 January 2026
- journal article
- Published by Wiley in Drug Development Research
- Vol. 87 (1) , e70228
Abstract
Mediated by their protein transduction domain, cell‐penetrating peptides (CPPs) have been widely explored for facilitating intracellular delivery of drugs and small molecules. In this study, a radiolabeled, 2‐nitroimidazole conjugated TAT (TAT ‐ transactivator of transcription) peptide was prepared and evaluated for targeting tumor hypoxia. The conjugate was radiolabeled with iodine‐125 and comprehensive in vitro and in vivo evaluations were conducted to assess its potential to target hypoxic cells. A radiolabeled [ 125 I]I‐TAT was also prepared as a control. In vitro studies carried out in CHO cells under hypoxic conditions revealed three fold uptake of [ 125 I]I‐TAT‐2‐NIM compared to [ 125 I]I‐TAT at 1 h post‐incubation, which further increased sixfold at 4 h post‐incubation, clearly demonstrating the role of nitroimidazole in targeting hypoxic cells. However, the study also revealed a negative influence of hypoxia in cellular uptake, wherein the radiolabeled TAT peptides showed a lower uptake in cells under hypoxic conditions than in normoxic conditions. In vivo, [ 125 I]I‐TAT‐2‐NIM showed uptake and retention in the tumor with the tumor/muscle ratio above 2 at all time points studied. However, the tumor/blood ratio was found to decrease with time. Though [ 12 5 I]I‐TAT‐2‐NIM showed higher accumulation in hypoxic cells compared to [ 125 I]I‐TAT in vitro, the negative influence of hypoxia on the cellular uptake of TAT‐peptides possibly indicates their limitation for hypoxia targeting applications.Keywords
This publication has 56 references indexed in Scilit:
- Transactivator of Transcription Fusion Protein Transduction Causes Membrane InversionJournal of Biological Chemistry, 2004
- Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancerActa Oncologica, 2004
- Intracellular Delivery of p53 Fused to the Basic Domain of HIV-1 TatMolecules and Cells, 2004
- Antitumour effects of PLC-γ1-(SH2)2-TAT fusion proteins on EGFR/c-erbB-2-positive breast cancer cellsBritish Journal of Cancer, 2004
- Novel Tat-Peptide Chelates for Direct Transduction of Technetium-99m and Rhenium into Human Cells for Imaging and RadiotherapyBioconjugate Chemistry, 2000
- Protein transduction: unrestricted delivery into all cells?Trends in Cell Biology, 2000
- Targeting Hypoxia in Tumors Using 2-Nitroimidazoles with Peptidic Chelators for Technetium-99m: Effect of LipophilicityBioconjugate Chemistry, 2000
- Nitroimidazoles and imaging hypoxiaEuropean Journal of Nuclear Medicine and Molecular Imaging, 1995
- A RADIOSYNTHESIS OF F-18 FLUOROMISONIDAZOLE1989
- Electron-Affinic Sensitization: VII. A Correlation between Structures, One-Electron Reduction Potentials, and Efficiencies of Nitroimidazoles as Hypoxic Cell RadiosensitizersRadiation Research, 1976